Transcriptional Silencing Is Defined by Isoform- and Heterodimer-Specific Interactions between Nuclear Hormone Receptors and Corepressors

ABSTRACT Nuclear hormone receptors are ligand-regulated transcription factors that play critical roles in metazoan homeostasis, development, and reproduction. Many nuclear hormone receptors exhibit bimodal transcriptional properties and can either repress or activate the expression of a given target gene. Repression appears to require a physical interaction between a receptor and a corepressor complex containing the SMRT/TRAC or N-CoR/RIP13 polypeptides. We wished to better elucidate the rules governing the association of receptors with corepressors. We report here that different receptors interact with different domains in the SMRT and N-CoR corepressors and that these divergent interactions may therefore contribute to distinct repression phenotypes. Intriguingly, different isoforms of a single nuclear hormone receptor class also differ markedly in their interactions with corepressors, indicative of their nonidentical actions in cellular regulation. Finally, we present evidence that combinatorial interactions between different receptors can, through the formation of heterodimeric receptors, result in novel receptor-corepressor interactions not observed for homomeric receptors.

[1]  J. Buchan.  Flexible friends. , 2000, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[2]  M. Lazar,et al.  Differential recognition of liganded and unliganded thyroid hormone receptor by retinoid X receptor regulates transcriptional repression , 1997, Molecular and cellular biology.

[3]  Hui Li,et al.  Characterization of receptor interaction and transcriptional repression by the corepressor SMRT. , 1997, Molecular endocrinology.

[4]  M. Privalsky,et al.  A conformational switch in nuclear hormone receptors is involved in coupling hormone binding to corepressor release , 1997, Molecular and cellular biology.

[5]  D. Leprince,et al.  Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[6]  A. Dejean,et al.  SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor α (RARα) and PLZF-RARα oncoproteins associated with acute promyelocytic leukemia , 1997 .

[7]  K. Horwitz,et al.  The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. , 1997, Molecular endocrinology.

[8]  B. O’Malley,et al.  Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. , 1997, Molecular endocrinology.

[9]  B. O’Malley,et al.  Gene silencing by chicken ovalbumin upstream promoter-transcription factor I (COUP-TFI) is mediated by transcriptional corepressors, nuclear receptor-corepressor (N-CoR) and silencing mediator for retinoic acid receptor and thyroid hormone receptor (SMRT). , 1997, Molecular endocrinology.

[10]  M. Pazin,et al.  What's Up and Down with Histone Deacetylation and Transcription? , 1997, Cell.

[11]  A. Wolffe.  Sinful repression , 1997, nature.

[12]  M. Privalsky,et al.  Plasticity of Tetramer Formation by Retinoid X Receptors , 1997, The Journal of Biological Chemistry.

[13]  V. Chatterjee,et al.  Thyroid hormone resistance syndrome manifests as an aberrant interaction between mutant T3 receptors and transcriptional corepressors. , 1997, Molecular endocrinology.

[14]  M. Lazar,et al.  Stoichiometric and steric principles governing repression by nuclear hormone receptors. , 1997, Genes & development.

[15]  R. Evans,et al.  The phantom ligand effect: allosteric control of transcription by the retinoid X receptor. , 1997, Genes & development.

[16]  D. Moore,et al.  Two receptor interacting domains in the nuclear hormone receptor corepressor RIP13/N-CoR. , 1996, Molecular endocrinology.

[17]  M. Downes,et al.  Two receptor interaction domains in the corepressor, N-CoR/RIP13, are required for an efficient interaction with Rev-erbA alpha and RVR: physical association is dependent on the E region of the orphan receptors. , 1996, Nucleic acids research.

[18]  K. Horwitz,et al.  Nuclear receptor coactivators and corepressors. , 1996, Molecular endocrinology.

[19]  K. Umesono,et al.  SMRT isoforms mediate repression and anti-repression of nuclear receptor heterodimers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Privalsky,et al.  Identification of TRACs (T3 receptor-associating cofactors), a family of cofactors that associate with, and modulate the activity of, nuclear hormone receptors. , 1996, Molecular endocrinology.

[21]  R. Evans,et al.  Activation and repression by nuclear hormone receptors: hormone modulates an equilibrium between active and repressive states , 1996, Molecular and cellular biology.

[22]  M. Karin,et al.  A shift in the ligand responsiveness of thyroid hormone receptor alpha induced by heterodimerization with retinoid X receptor alpha , 1996, Molecular and cellular biology.

[23]  R. Evans,et al.  The RXR heterodimers and orphan receptors , 1995, Cell.

[24]  Philippe Kastner,et al.  Nonsteroid nuclear receptors: What Are genetic studies telling us about their role in real life? , 1995, Cell.

[25]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[26]  Miguel Beato,et al.  Steroid hormone receptors: Many Actors in search of a plot , 1995, Cell.

[27]  Thorsten Heinzel,et al.  Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor , 1995, Nature.

[28]  Myles Brown,et al.  Polarity-specific activities of retinoic acid receptors determined by a co-repressor , 1995, Nature.

[29]  R. Evans,et al.  A transcriptional co-repressor that interacts with nuclear hormone receptors , 1995, Nature.

[30]  R. Fletterick,et al.  The Molecular Biology of Thyroid Hormone Action , 1995, Annals of the New York Academy of Sciences.

[31]  K. Umesono,et al.  Unique response pathways are established by allosteric interactions among nuclear hormone receptors , 1995, Cell.

[32]  G. Adelmant,et al.  Nuclear Receptors: Lonesome orphans , 1995, Current Biology.

[33]  M. Privalsky,et al.  Cooperative formation of high-order oligomers by retinoid X receptors: an unexpected mode of DNA recognition. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[34]  B. O’Malley,et al.  The tau 4 activation domain of the thyroid hormone receptor is required for release of a putative corepressor(s) necessary for transcriptional silencing , 1995, Molecular and cellular biology.

[35]  D. Moore,et al.  Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. , 1995, Molecular endocrinology.

[36]  C. Glass,et al.  Regulation of retinoid signalling by receptor polarity and allosteric control of ligand binding , 1994, Nature.

[37]  B. Raaka,et al.  Functional evidence for ligand-dependent dissociation of thyroid hormone and retinoic acid receptors from an inhibitory cellular factor , 1994, Molecular and cellular biology.

[38]  C. Carlberg,et al.  Vitamin D3-thyroid hormone receptor heterodimer polarity directs ligand sensitivity of transactivation , 1994, Nature.

[39]  C. Glass.  Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers. , 1994, Endocrine reviews.

[40]  F. Bogazzi,et al.  A novel heterodimerization partner for thyroid hormone receptor. Peroxisome proliferator-activated receptor. , 1994, The Journal of biological chemistry.

[41]  P Chambon,et al.  The retinoid signaling pathway: molecular and genetic analyses. , 1994, Seminars in cell biology.

[42]  B. O’Malley,et al.  Molecular mechanisms of action of steroid/thyroid receptor superfamily members. , 1994, Annual review of biochemistry.

[43]  B. O’Malley,et al.  Ligand-dependent conformational changes in thyroid hormone and retinoic acid receptors are potentially enhanced by heterodimerization with retinoic X receptor , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[44]  M. Privalsky,et al.  The erbA oncogene represses the actions of both retinoid X and retinoid A receptors but does so by distinct mechanisms , 1993, Molecular and cellular biology.

[45]  M. Privalsky,et al.  Nuclear hormone receptors involved in neoplasia: erb A exhibits a novel DNA sequence specificity determined by amino acids outside of the zinc-finger domain , 1993, Molecular and cellular biology.

[46]  K. Umesono,et al.  Functional inhibition of retinoic acid response by dominant negative retinoic acid receptor mutants. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[47]  M. Lazar.  Thyroid hormone receptors: multiple forms, multiple possibilities. , 1993, Endocrine reviews.

[48]  R. Renkawitz,et al.  A transferable silencing domain is present in the thyroid hormone receptor, in the v‐erbA oncogene product and in the retinoic acid receptor. , 1992, The EMBO journal.

[49]  J. Dixon,et al.  Eukaryotic proteins expressed in Escherichia coli: an improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase. , 1991, Analytical biochemistry.

[50]  Forman Bm,et al.  Dimerization among nuclear hormone receptors. , 1990 .

[51]  H. Samuels,et al.  Dimerization among nuclear hormone receptors. , 1990, The New biologist.

[52]  C. Glass,et al.  Positive and negative regulation of gene transcription by a retinoic acid-thyroid hormone receptor heterodimer , 1989, Cell.

[53]  H. Stunnenberg,et al.  Repression of transcription mediated at a thyroid hormone response element by the v-erb-A oncogene product , 1989, Nature.

[54]  Klaus Damm,et al.  Protein encoded by v-erbA functions as a thyroid-hormone receptor antagonist , 1989, Nature.